Pavlo Petakh, Vasilij Griga, Issah Bin Mohammed, Kateryna Loshak, Ivan Poliak, Aleksandr Kamyshnyiy
{"title":"二甲双胍、胰岛素对新冠肺炎合并2型糖尿病患者血液学指标的影响","authors":"Pavlo Petakh, Vasilij Griga, Issah Bin Mohammed, Kateryna Loshak, Ivan Poliak, Aleksandr Kamyshnyiy","doi":"10.5455/medarh.2022.76.329-332","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 infection caused by SARS-COV-2 can result in multi-organ injuries and significant mortality in severe and critical patients, particularly those with type 2 diabetes as a comorbidity. Metformin and insulin are the main diabetes medications that affect the outcome of patients with COVID-19.</p><p><strong>Objective: </strong>The purpose of our study was to find out the features of the hematological indicators of patients with COVID-19 patients and type 2 diabetes.</p><p><strong>Methods: </strong>This is a retrospective study of the hospital confirmed COVID-19 patients between January to March 2022, who were admitted to Transcarpathian Regional Clinical Infectious Diseases Hospital (Uzhhorod, Ukraine).</p><p><strong>Results: </strong>The effect of type 2 diabetes, metformin, and insulin on COVID-19 were analyzed, respectively. Demographics and blood laboratory indices were collected. In patients who took metformin, the level of CRP was significantly lower than in patients who did not take metformin (24 mg/L [IQR 15 - 58] vs 52 mg/L, [IQR 22-121], P = 0.046).</p><p><strong>Conclusion: </strong>Our findings suggest that pre-admission metformin use may benefit COVID-19 patients with type 2 diabetes.</p>","PeriodicalId":18421,"journal":{"name":"Medicinski arhiv","volume":"76 5","pages":"329-332"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/bc/medarch-76-329.PMC9760238.pdf","citationCount":"7","resultStr":"{\"title\":\"Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes.\",\"authors\":\"Pavlo Petakh, Vasilij Griga, Issah Bin Mohammed, Kateryna Loshak, Ivan Poliak, Aleksandr Kamyshnyiy\",\"doi\":\"10.5455/medarh.2022.76.329-332\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>COVID-19 infection caused by SARS-COV-2 can result in multi-organ injuries and significant mortality in severe and critical patients, particularly those with type 2 diabetes as a comorbidity. Metformin and insulin are the main diabetes medications that affect the outcome of patients with COVID-19.</p><p><strong>Objective: </strong>The purpose of our study was to find out the features of the hematological indicators of patients with COVID-19 patients and type 2 diabetes.</p><p><strong>Methods: </strong>This is a retrospective study of the hospital confirmed COVID-19 patients between January to March 2022, who were admitted to Transcarpathian Regional Clinical Infectious Diseases Hospital (Uzhhorod, Ukraine).</p><p><strong>Results: </strong>The effect of type 2 diabetes, metformin, and insulin on COVID-19 were analyzed, respectively. Demographics and blood laboratory indices were collected. In patients who took metformin, the level of CRP was significantly lower than in patients who did not take metformin (24 mg/L [IQR 15 - 58] vs 52 mg/L, [IQR 22-121], P = 0.046).</p><p><strong>Conclusion: </strong>Our findings suggest that pre-admission metformin use may benefit COVID-19 patients with type 2 diabetes.</p>\",\"PeriodicalId\":18421,\"journal\":{\"name\":\"Medicinski arhiv\",\"volume\":\"76 5\",\"pages\":\"329-332\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/bc/medarch-76-329.PMC9760238.pdf\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicinski arhiv\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/medarh.2022.76.329-332\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinski arhiv","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/medarh.2022.76.329-332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 7
摘要
背景:SARS-COV-2引起的COVID-19感染可导致重症和危重症患者多器官损伤和显著死亡率，特别是合并2型糖尿病患者。二甲双胍和胰岛素是影响COVID-19患者预后的主要糖尿病药物。目的:了解新冠肺炎患者与2型糖尿病患者血液学指标的特点。方法:对2022年1月至3月在乌克兰乌日霍罗德跨喀尔巴阡地区临床传染病医院住院的新冠肺炎确诊患者进行回顾性研究。结果:分别分析2型糖尿病、二甲双胍和胰岛素对COVID-19的影响。收集人口统计学和血液实验室指标。在服用二甲双胍的患者中，CRP水平明显低于未服用二甲双胍的患者(24 mg/L [IQR 15 - 58] vs 52 mg/L， [IQR 22-121]， P = 0.046)。结论:我们的研究结果表明，入院前使用二甲双胍可能使COVID-19合并2型糖尿病患者受益。
Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes.
Background: COVID-19 infection caused by SARS-COV-2 can result in multi-organ injuries and significant mortality in severe and critical patients, particularly those with type 2 diabetes as a comorbidity. Metformin and insulin are the main diabetes medications that affect the outcome of patients with COVID-19.
Objective: The purpose of our study was to find out the features of the hematological indicators of patients with COVID-19 patients and type 2 diabetes.
Methods: This is a retrospective study of the hospital confirmed COVID-19 patients between January to March 2022, who were admitted to Transcarpathian Regional Clinical Infectious Diseases Hospital (Uzhhorod, Ukraine).
Results: The effect of type 2 diabetes, metformin, and insulin on COVID-19 were analyzed, respectively. Demographics and blood laboratory indices were collected. In patients who took metformin, the level of CRP was significantly lower than in patients who did not take metformin (24 mg/L [IQR 15 - 58] vs 52 mg/L, [IQR 22-121], P = 0.046).
Conclusion: Our findings suggest that pre-admission metformin use may benefit COVID-19 patients with type 2 diabetes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
